Literature DB >> 3096134

Hepatic fibrosis in the mucopolysaccharidoses.

N A Parfrey, G M Hutchins.   

Abstract

The mucopolysaccharidoses are a group of clinically progressive, heritable, lysosomal storage disorders. Many organ systems are affected due to widespread accumulation of incompletely degraded mucopolysaccharide. The novel finding of hepatic fibrosis in each of six cases of mucopolysaccharidosis examined at autopsy (including examples of Hurler syndrome, Hunter syndrome, and Sanfilippo syndrome) is described. In each instance, the liver was diffusely involved by fibrosis that outlined the lobules, and there was extensive hepatocyte and Kupffer cell vacuolization. The pattern of hepatic fibrosis is not explained by either cardiac failure or drug toxicity. It is hypothesized that the hepatic fibrosis is due to the abnormal accumulation of a hepatotoxic metabolite. The frequency and severity of liver disease in the mucopolysaccharidoses deserve further study. In particular, with the advent of bone marrow transplantation as therapy for some of the mucopolysaccharidoses, the question of whether cirrhosis develops in these patients and, if so, what its rate of progression is, should be addressed.

Entities:  

Mesh:

Year:  1986        PMID: 3096134     DOI: 10.1016/0002-9343(86)90353-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  2 in total

1.  Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.

Authors:  Jee Hyun Lee; Yon Ho Choe; Su Jin Kim; Kyung Hoon Paik; Dong-Kyu Jin
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

2.  Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses.

Authors:  Estera Rintz; Lidia Gaffke; Magdalena Podlacha; Joanna Brokowska; Zuzanna Cyske; Grzegorz Węgrzyn; Karolina Pierzynowska
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.